Milestone: First TCR-T Therapy Files for Approval
- Why Lecanemab’s Adoption Faces an Uphill Battle in US?
- Yogurt and High LDL Cholesterol: Can You Still Enjoy It?
- WHO Releases Global Influenza Vaccine Market Study in 2024
- HIV Infections Linked to Unlicensed Spa’s Vampire Facial Treatments
- A Single US$2.15-Million Injection to Block 90% of Cancer Cell Formation
- WIV: Prevention of New Disease X and Investigation of the Origin of COVID-19
Milestone: First TCR-T Therapy Files for Approval
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Milestone: First TCR-T Therapy Files for Approval
On January 31, 2024, Adaptimmune announced that the market application for their TCR-T therapy, Afami-cel, has been accepted by the FDA and granted priority review status, with a PDUFA date set for August 4 of this year.
Afami-cel marks Adaptimmune’s inaugural pipeline, targeting MAGE-A4, designed for the treatment of a type of soft tissue tumor known as synovial sarcoma.
This therapy holds the potential to be the first T-cell therapy for solid tumors, making it a groundbreaking achievement if successfully approved.
Synovial sarcoma, a subtype of soft tissue tumors, accounts for approximately 5-10% of the 13,000 new cases of soft tissue tumors diagnosed annually in the United States. The five-year survival rate for synovial sarcoma is merely 20%, highlighting a significant unmet clinical need.
Adaptimmune anticipates a peak sales value of $400 million for the combined Afami-cel and lete-cel therapies.
Afami-cel has demonstrated a 39% Objective Response Rate (ORR) in later-line treatments.
With a two-year survival rate of 70%, Afami-cel’s median Overall Survival (mOS) is estimated at 17 months, surpassing historical data with a comparison of less than 12 months.
In summary, the success of Afami-cel is a milestone, indicating a shift in cancer treatment targets from membrane/extracellular to intracellular domains, opening up new possibilities in target selection.
The approval of Afami-cel is eagerly awaited, offering improved treatment options for synovial sarcoma patients.
Milestone: First TCR-T Therapy Files for Approval
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
